| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.062 | 0.04 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | -0.063 | 0.05 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.05 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.073 | 0.05 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.22 | 0.05 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | -0.06 | 0.06 |